Emerging therapeutic approaches in renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 15, Issue 11, 2015, Pages 1305-1314

  Parekh, Hiral ^a   Rini, Brian I ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

anti programmed death 1 therapies; immunotherapy; ipilimumab; nivolumab; renal cell carcinoma; targeted therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CXCL9 CHEMOKINE; EVEROLIMUS; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G4; INTERLEUKIN 2; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MPDL 3280A; NIVOLUMAB; PAZOPANIB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER IMMUNOTHERAPY; COLITIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY PELVIS; LOSS OF APPETITE; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DISEASE COURSE; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84948107042     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1090315     Document Type: Review

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer. J Clin 2013; 63 (1): 11-30
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353 (23): 2477-90
3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13 (3): 688-96
4. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113 (2): 293-301
5. Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013; 108 (12): 2470-7
6. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010; 36 (5): 416-24
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22): 3584-90
8. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind Phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49 (6): 1287-96
9. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369 (8): 722-31
10. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase III trial. Lancet Oncol 2013; 14 (6): 552-62
11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378 (9807): 1931-9
12. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27 (20): 3312-18
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356 (2): 125-34
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356 (22): 2271-81
15. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116 (18): 4256-65
16. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30 (12): 1371-7
17. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014; 191 (3): 611-18
18. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014; 50 (6): 1084-9
19. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24 (1): 25-35
20. Sunitinib scheduling in metastatic renal cell carcinoma (mRCC). Available from: https://clinicaltrials.gov/ct2/show/NCT02060370
21. Rini BI, Melichar B, Fishman MN, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015; 26 (7): 1372-7
22. Rini BI, Melichar BTY. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. J Clin Oncol 2015; 33: suppl; abstr 4545
23. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (9): 1432-9
24. Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009; 15 (19): 6277-83
25. Sosman J, Atkins MFK, McDermott D, et al. Updated results of phase I trial of sorafenib and bevacizumab in patient with metastatic renal cell cancer. J Clin Oncol 2008; 26 (Suppl): abstract 5011
26. McDermott D, Pins MMJ, Flaherty K, et al. The BeST Trial (ECOG 2804): a randomized phase II study of VEGF, RAF kinase, and MTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma. J Clin Oncol 2013; 31 (Suppl 6; abstract 345
27. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014; 32 (8): 752-9
28. Ravaud A, Anak OBC. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferonalfa-2a(IFN) + BEV inpatients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. Ann Oncol 2012; 23: 7830; Meeting abstracts
29. Motzer R, Glen HHT, Michaelson D, et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN + EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33: suppl; abstr 4506
30. Eskens FA, de Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res 2011; 17 (22): 7156-63
31. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31 (30): 3791-9
32. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 2013; 15 (2): 76-82
33. Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014; 25 (8): 1603-8
34. Cabozantinib-s-malate or sunitinib malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01835158
35. A study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma (METEOR). Available from: https://clinicaltrials.gov/ct2/show/NCT01865747
36. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192 (7): 1027-34
37. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24 (2): 207-12
38. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12 (4): 252-64
39. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (8): 793-800
40. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8 (6): 467-77
41. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114 (8): 1537-44
42. Drake CG, Sznol M, et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. Clin Oncol 2013; suppl; abstr 4514
43. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015; 33 (13): 1430-7
44. Plimack ER, Rini BI. Updated survival results from a randomized, dose-ranging Phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33: suppl; abstr 4553
45. Study of nivolumab (BMS-936558) vs everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (CheckMate 025). Available from: https://clinicaltrials.gov/ct2/show/NCT01668784
46. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366 (26): 2455-65
47. Cho DC, Sznol M. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; suppl; abstr 4505
48. Amin A, Infante JR, Ernstoff MS, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32: 5s-suppl; abstr 5010
49. Nivolumab (BMS-936558; MDX-1106) in combination with sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma (RCC) (CheckMate 016). Available from: https://clinicaltrials.gov/ct2/show/NCT01472081
50. McDermott DF, Sosman JA. Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol Proceedings of the European Society of Medical Oncology Meeting 2014, Madrid, 2014,. Abstract 809O
51. A phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as monotherapy or in combination with avastin (bevacizumab) compared to sunitinib in patients with untreated advanced renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01984242
52. A Study of MPDL3280A (Anti-programmed death ligand 1 [PD-L1] Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02420821
53. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-94
54. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30 (8): 825-30
55. Hammers HJ, Infante JR. Expanded cohort results from CheckMate 016: A Phase 1 study of nivolumab in combination with ipilimumab in the metastatic renal cell carcinoma (mRCC). J Clinc Oncol 2015; 33: suppl; abstr 4516
56. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214). Available from: https://clinicaltrials.gov/ct2/show/NCT02231749
57. Choueiri TK, Escudier BJ. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 2014; 32: 5s-suppl; abstr 5012
58. Choueiri TK, Escudier BJ. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. J Clin Oncol 2015; 33: suppl; abstr 4500
59. Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69 (6): 2506-13
60. Sharpe K, Stewart GD, Mackay A, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 2013; 19 (24): 6924-34
61. A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies (MDX1106-03). Available from: https://clinicaltrials.gov/ct2/show/NCT00730639
62. Phase I Biomarker Study (BMS-936558). Available from: https://clinicaltrials.gov/ct2/show/NCT01358721
63. BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC). Available from: https://clinicaltrials.gov/ct2/show/NCT01354431
64. A Phase 1 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with locally advanced or metastatic solid tumors. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01375842